Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04222712) enrolled 16 people in total, split into two groups of 8 — one group received a lower dose of a treatment called TRS01, and the other received a higher dose. All 16 participants completed the study with no one dropping out. The trial was measuring adverse events, meaning any unwanted or unexpected health experiences that occurred during the study, both in the eyes and throughout the body more broadly. The reported data shows that in the low dose group, 2 out of 8 participants experienced adverse events during the study. In the high dose group, 5 out of 8 participants experienced adverse events. This was the only outcome measure reported in the structured results submitted to ClinicalTrials.gov. No other outcome figures — such as measures of how well the treatment may have worked — were included in the data provided. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You are able to give your consent to participate, follow instructions, and attend all required appointments for the full length of the study
- You have been diagnosed with active non-infectious anterior uveitis (inflammation at the front of the eye that is not caused by infection) that needs treatment with steroid eye drops, either starting them for the first time or increasing the dose
- You have a specific level of eye inflammation (measured by cells in the front chamber of the eye, rated as Grade 2 or Grade 3 — confirm with trial site)
- Your vision in the eye that is NOT being studied is 20/40 or better (similar to passing a standard driving vision test)
- If you are able to have children and are sexually active, you are using an adequate form of birth control (specific requirements to be confirmed with trial site)
Who may not be able to join:
- Your uveitis is caused by an infection
- You currently have active inflammation of the retina (the light-sensitive layer at the back of the eye)
- You have cancer or melanoma (a type of skin cancer) that is currently being treated with immunotherapy
- You are pregnant or breastfeeding
- You are currently taking certain medications or receiving certain treatments that are not permitted in this study (confirm with trial site for the specific details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assessment of Both Systemic and Ocular Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.